David della Lana
Family Medicine · Santa Rosa, CANPI 1356449029
Payments from drug & device makers
Across 77 payments — averaging $680.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$42K
- Eli Lilly$10K
- Boehringer Ingelheim$238
- Novo Nordisk$113
- Johnson & Johnson$99
- Teva Pharmaceuticals USA, Inc.$89
- plus $529 from 14 others
Across 2 payments — averaging $602.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
What the payments were for
- Food & beverage$1,068100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 9 | $41,584 |
| Eli Lilly | 5 | $9,761 |
| Boehringer Ingelheim | 10 | $238 |
| Novo Nordisk | 10 | $113 |
| Johnson & Johnson | 6 | $99 |
| Teva Pharmaceuticals USA, Inc. | 6 | $89 |
| Amgen | 4 | $78 |
| Astellas Pharma US Inc | 3 | $63 |
| Edwards Lifesciences | 3 | $61 |
| Pfizer | 4 | $54 |
| AstraZeneca | 3 | $46 |
| Merck | 3 | $43 |
| Organon | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Sanofi Pasteur Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Novartis | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $14 |
| GSK | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
How this compares
$52,412 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $28,516 |
| BelbucaBuprenorphine Hcl | 17 | $14,233 |
| Spiriva RespimatTiotropium Bromide | 16 | $9,874 |
| PradaxaDabigatran Etexilate Mesylate | 33 | $8,780 |
| BreynaBudesonide/Formoterol Fumarate | 43 | $8,308 |
| Victoza 2-PakLiraglutide | 13 | $8,109 |
| JardianceEmpagliflozin | 14 | $7,225 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 124 | $3,666 |
| AlvescoCiclesonide | 26 | $2,992 |
| Levothyroxine Sodium | 144 | $2,793 |
| Atorvastatin Calcium | 228 | $2,767 |
| Gabapentin | 71 | $1,749 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 75 | $1,746 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 45 | $1,702 |
| Fluticasone Propionate | 73 | $1,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $113 | $28,51637 claims |
| Boehringer IngelheimSpiriva Respimat, Pradaxa, Jardiance | $238 | $25,87963 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $89 | $1,00140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Santa Rosa
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.